| TITLE |
DATE |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2010 Financial Results |
8-Aug-2010 |
| Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2010 Financial Results |
5-Aug-2010 |
| Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors |
21-Jul-2010 |
| Keryx Biopharmaceuticals Receives Orphan Drug Designation for KRX-0401 (Perifosine) for the Treatment of Neuroblastoma |
14-Jul-2010 |
| Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the Upcoming 12th World Congress on Gastrointestinal Cancer |
29-Jun-2010 |
| Keryx Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colorectal Cancer |
8-Jun-2010 |
| Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma |
7-Jun-2010 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations |
3-Jun-2010 |
| Keryx Biopharmaceuticals Announces Presentation of Two Abstracts at ASCO 2010 Annual Meeting |
21-May-2010 |
| Publication in the Journal of the National Cancer Institute Demonstrates KRX-0401 (Perifosine) Single-Agent Potential in Neuroblastoma Tumors |
17-May-2010 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations |
14-May-2010 |
| Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2010 Financial Results |
10-May-2010 |
| Keryx Biopharmaceuticals Initiates Phase 3 Registration Program of Zerenex (ferric citrate) for the Treatment of Patients with Hyperphosphatemia |
6-May-2010 |
| Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Preclinical Activity of Single-Agent KRX-0401 (Perifosine) at 2010 AACR Annual Meeting |
20-Apr-2010 |
| Keryx Biopharmaceuticals Reports Updated Long-Term Data of Zerenex (ferric citrate) Presented at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings |
15-Apr-2010 |
| Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of Zerenex (ferric citrate) at National Kidney Foundation (NKF) 2010 Spring Clinical Meetings |
13-Apr-2010 |
| Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Refractory Advanced Colorectal Cancer |
8-Apr-2010 |
| Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer |
5-Apr-2010 |
| Keryx Biopharmaceuticals, Inc. To Hold Conference Call on Fourth Quarter and Year-End 2009 Financial Results on Thursday, March 25, 2010 at 8:30 a.m. EDT |
23-Mar-2010 |
| Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference |
10-Mar-2010 |
| Keryx Biopharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference |
5-Mar-2010 |
| Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer |
3-Feb-2010 |
| Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference |
2-Feb-2010 |
| Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia |
29-Jan-2010 |
| Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer |
27-Jan-2010 |
| Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer |
25-Jan-2010 |
| Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cancers Symposium |
21-Jan-2010 |
| Keryx Biopharmaceuticals to Present at the J.P. Morgan 28th Annual Healthcare Conference |
7-Jan-2010 |
| Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in the Treatment of Hyperphosphatemia |
5-Jan-2010 |
| Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma |
16-Dec-2009 |
| Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology |
7-Dec-2009 |
| Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma |
2-Dec-2009 |
| Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference |
24-Nov-2009 |
| Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology |
11-Nov-2009 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST |
6-Nov-2009 |
| Keryx Biopharmaceuticals to Present at the Merriman Curhan Ford 6th Annual Investor Summit |
4-Nov-2009 |
| Keryx Biopharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference |
29-Oct-2009 |
| Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego |
26-Oct-2009 |
| Phase 2 Study of KRX-0401 (Perifosine) in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Open for Enrollment at Duke Comprehensive Cancer Center |
8-Oct-2009 |
| Updated Single Agent Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Carcinoma Reported at the Eighth International Kidney Cancer Symposium |
29-Sep-2009 |
| Keryx Biopharmaceuticals, Inc. to Raise $20 Million in Registered Direct Offering |
25-Sep-2009 |
| Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia |
23-Sep-2009 |
| Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow |
21-Sep-2009 |
| Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium |
14-Sep-2009 |
| Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day |
31-Aug-2009 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT |
4-Aug-2009 |
| Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann |
4-Aug-2009 |
| Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma |
3-Aug-2009 |
| Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center |
14-Jul-2009 |
| Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements |
17-Jun-2009 |
| Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance |
9-Jun-2009 |
| Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients |
8-Jun-2009 |
| Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer |
1-Jun-2009 |
| Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer |
31-May-2009 |
| Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer |
29-May-2009 |
| Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer |
20-May-2009 |
| Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology |
18-May-2009 |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results |
13-May-2009 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT |
11-May-2009 |
| Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer |
23-Apr-2009 |
| Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research |
21-Apr-2009 |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results |
12-Mar-2009 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT |
11-Mar-2009 |
| Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq |
9-Mar-2009 |
| Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification |
5-Mar-2009 |
| Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting |
26-Feb-2009 |
| Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference |
13-Jan-2009 |
| Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology |
9-Dec-2008 |
| Keryx Biopharmaceuticals Receives Nasdaq Notification |
21-Nov-2008 |
| Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology |
10-Nov-2008 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST |
7-Nov-2008 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT |
7-Aug-2008 |
| Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference |
24-Jun-2008 |
| Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology |
3-Jun-2008 |
| Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois |
2-Jun-2008 |
| Keryx Biopharmaceuticals to Present at the Bank of America 2008 Health Care Conference |
13-May-2008 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT |
8-May-2008 |
| Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference |
5-May-2008 |
| Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan |
4-Apr-2008 |
| Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial |
27-Mar-2008 |
| Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference |
13-Mar-2008 |
| Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint |
10-Mar-2008 |
| Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint |
7-Mar-2008 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST |
21-Feb-2008 |
| Keryx Biopharmaceuticals Announces Additions to Management Team |
15-Feb-2008 |
| Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial |
11-Feb-2008 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations |
5-Feb-2008 |
| Keryx Biopharmaceuticals to Present at JPMorgan Healthcare Conference |
3-Jan-2008 |
| Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology |
10-Dec-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia |
7-Dec-2007 |
| Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data |
5-Dec-2007 |
| Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology |
19-Nov-2007 |
| Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium |
9-Nov-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma |
5-Nov-2007 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations |
2-Nov-2007 |
 |
| TITLE |
DATE |
| Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period |
23-Oct-2008 |
| Keryx Biopharmaceuticals Receives Nasdaq Notification |
25-Apr-2008 |
| Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results |
24-Oct-2007 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT |
23-Oct-2007 |
| Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference |
2-Oct-2007 |
| Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan |
26-Sep-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance |
26-Sep-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors |
21-Sep-2007 |
| Keryx Biopharmaceuticals to Present at Bank of America Investment Conference |
17-Sep-2007 |
| Keryx Biopharmaceuticals to Present at Bear Stearns Healthcare Conference |
6-Sep-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2007 Financial Results |
25-Jul-2007 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2007 Financial Results on Thursday, July 26, at 8:30 A.M. EDT |
24-Jul-2007 |
| William P. Kane Named Vice President, Commercial Operations for Keryx Biopharmaceuticals, Inc. |
17-Jul-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia |
29-Jun-2007 |
| Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference |
25-Jun-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois |
22-Jun-2007 |
| Keryx Biopharmaceuticals Announces Completion of Patient Randomization Into Sulonex Phase III Pivotal Study |
18-Jun-2007 |
| Keryx Biopharmaceuticals Announces Financial Management Change |
18-Jun-2007 |
| Keryx Biopharmaceuticals to Present at The Bank of America 2007 Health Care Conference |
23-May-2007 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations |
26-Apr-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Appointment of Kevin J. Cameron to Board of Directors |
25-Apr-2007 |
| Keryx Biopharmaceuticals Names Beth F. Levine as Senior Vice President, General Counsel & Chief Compliance Officer |
25-Apr-2007 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2007 Financial Results on Thursday, April 26, at 8:30 A.M. EDT |
24-Apr-2007 |
| Keryx Biopharmaceuticals Names Mark Stier, CPA Chief Accounting Officer |
27-Mar-2007 |
| Keryx Biopharmaceuticals to Present at Lehman Brothers' 10th Annual Global Healthcare Conference |
16-Mar-2007 |
| Keryx Biopharmaceuticals to Present at the Cowen and Company 27th Annual Health Care Conference |
8-Mar-2007 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2006 Financial Results |
6-Mar-2007 |
| Keryx Biopharmaceuticals to Present at the 9th Annual BIO CEO & Investor Conference |
9-Feb-2007 |
| Keryx Biopharmaceuticals to Present at the Merrill Lynch 2007 Global Pharmaceutical, Biotechnology & Medical Device Conference |
1-Feb-2007 |
| Keryx Biopharmaceuticals to Present at the 25th Annual JPMorgan Healthcare Conference |
3-Jan-2007 |
| The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma |
28-Dec-2006 |
| Keryx Biopharmaceuticals, Inc. Commences Phase II, Multi-Center Study of KRX-0401 for the Treatment of Rare Sarcomas |
13-Dec-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Positive Interim Phase II Data on KRX-0401 (Perifosine) in Patients with Relapsed and Refractory Multiple Myeloma (MM) |
11-Dec-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Clinical and Pre-Clinical Activity of KRX-0401 (Perifosine) at the Upcoming American Society of Hematology Annual Meeting in Orlando, Florida |
7-Dec-2006 |
| Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations |
10-Nov-2006 |
| Keryx Biopharmaceuticals to Present at the JPMorgan Small/Mid Cap Conference |
9-Nov-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Appointment of Former U.S. Senator Wyche Fowler, Jr. to Board of Directors |
8-Nov-2006 |
| Keryx Biopharmaceuticals to Present at the Cowen and Company 7th Annual Global Healthcare Conference |
2-Nov-2006 |
| Kyowa Hakko Grants Keryx Biopharmaceuticals Exclusive Rights to UCN-01, a Novel, Anticancer Agent in Phase II Clinical Development |
4-Oct-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Appointment of Jack Kaye, CPA, to Board of Directors |
20-Sep-2006 |
| Keryx Biopharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare Conference |
7-Sep-2006 |
| Keryx Announces Positive Final Results from Phase 2 Dose-Ranging Study of Zerenex™ for the Treatment of Hyperphosphatemia in Patients with End-stage Renal Disease |
29-Jun-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Positive Data Of KRX-0401 (Perifosine) In Patients With Advanced Renal Cell Carcinoma |
3-Jun-2006 |
| Keryx Biopharmaceuticals to Present at Lehman Brothers 9th Annual Healthcare Conference |
6-Mar-2006 |
| Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center Study of KRX-0401 for the Treatment of Refractory Leukemia |
2-Mar-2006 |
| Keryx Biopharmaceuticals to Present at Cowen & Co. 26th Annual Healthcare Conference |
2-Mar-2006 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2005 Financial Results on Thursday, March 2, at 8:30 A.M. EST |
28-Feb-2006 |
| Keryx Biopharmaceuticals Names Ronald C. Renaud, Jr. as Chief Financial Officer |
16-Feb-2006 |
| Keryx Biopharmaceuticals Announces Expansion of Renal Franchise With the In-Licensing of Zerenex™, a Novel Phosphate Binder |
15-Feb-2006 |
| Keryx Biopharmaceuticals, Inc. to Webcast KRX-101 Analyst Day on February 15, 2006 |
10-Feb-2006 |
| Keryx Biopharmaceuticals to Present at BIO CEO and Investor Conference |
10-Feb-2006 |
| Keryx Biopharmaceuticals to Present at The Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference |
3-Feb-2006 |
| Keryx Biopharmaceuticals to Present at the Brean Murray, Carret Small Cap Institutional Investor Conference |
30-Jan-2006 |
| Keryx Biopharmaceuticals to Present at the 24th Annual JPMorgan Healthcare Conference |
5-Jan-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Appointment of Senior Pharmaceutical Executive to Board of Directors |
4-Jan-2006 |
| Keryx Biopharmaceuticals, Inc. Commences Phase II, Multi-Center Study of KRX-0401 for the Treatment of Refractory Multiple Myeloma |
3-Jan-2006 |
| Ron Bentsur Accepts Position As CEO Of XTL Biopharmaceuticals, Ltd. |
30-Dec-2005 |
| Keryx Biopharmaceuticals, Inc. Announces Oral Presentation on KRX-0401 at the Upcoming American Society of Hematology Annual Meeting |
22-Dec-2005 |
| Keryx Biopharmaceuticals to Present at Lazard Capital Markets Life Sciences Conference |
25-Nov-2005 |
| Keryx Announces Positive Final Results from Phase 2 Clinical Study for KRX-101 (Sulodexide Gelcaps) for the Treatment of Diabetic Nephropathy |
14-Nov-2005 |
| Keryx Announces Positive Final Results from Phase 2 Clinical Study for KRX-101 (sulodexide gelcaps) for the Treatment of Diabetic Nephropathy |
11-Nov-2005 |
| Keryx Biopharmaceuticals to Present at JPMorgan Small Cap Conference |
31-Oct-2005 |
| Keryx Biopharmaceuticals, Inc, Announces Final Phase II Data Presentation on KRX-101 at the Upcoming American Society of Nephrology Renal Week |
24-Oct-2005 |
| Keryx Biopharmaceuticals, Inc. Announces Exercise of Over-Allotment Option by Underwriters |
18-Jul-2005 |
| Keryx Biopharmaceuticals, Inc. Announces Pricing of Common Stock Offering |
15-Jul-2005 |
| Keryx Biopharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock |
11-Jul-2005 |
| Keryx Biopharmaceuticals, Inc. Initiates Pivotal Phase 3 and Phase 4 Clinical Program of KRX-101 for Treatment of Diabetic Nephropathy |
29-Jun-2005 |
| Keryx Biopharmaceuticals to Present at Friedman Billings Ramsey 9th Annual Growth Conference |
31-May-2005 |
| Keryx Biopharmaceuticals to Present at Banc of America Securities Annual Health Care Conference |
17-May-2005 |
| Data from KRX-0401 Single Agent Phase 2 Study in Recurrent Prostate Cancer Presented at the American Society of Clinical Oncology Annual Meeting |
16-May-2005 |
| KERYX BIOPHARMACEUTICALS, INC, ANNOUNCES UPCOMING DATA PRESENTATION ON KRX-0401 AT THE AMERICAN SOCIETY OF ONCOLOGY ANNUAL MEETING |
11-May-2005 |
| Keryx Announces Positive Interim Results From Phase 2 Clinical Study for KRX-101 (Sulodexide Gelcaps) for Treatment of Diabetic Nephropathy |
6-May-2005 |
| Keryx Biopharmaceuticals Announces the Following Upcoming Corporate Presentations |
29-Mar-2005 |
| Keryx Biopharmaceuticals Finalizes Special Protocol Assessment (SPA) Agreement With FDA For KRX-101 Phase 3 and Phase 4 Clinical Trials |
16-Mar-2005 |
| KERYX ANNOUNCES RESULTS OF DATA SAFETY MONITORING COMMITTEE AND COLLABORATIVE STUDY GROUP (CSG) REVIEW OF FIRST INTERIM ANALYSIS FROM PHASE II/III CLINICAL PROGRAM FOR KRX-101 (ORAL SULODEXIDE) FOR THE TREATMENT OF DIABETIC NEPHROPATHY |
5-Jan-2005 |
| Keryx Biopharmaceuticals, Inc. to Present at the Fourth Annual Harris Nesbitt Focus on Healthcare Investor Conference |
7-Dec-2004 |
| Keryx Biopharmaceuticals, Inc. to Present at the CIBC World Markets Fifteenth Annual Healthcare Conference |
4-Nov-2004 |
| Keryx Biopharmaceuticals, Inc. to Present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference |
25-Oct-2004 |
| Data from KRX-0401 (Perifosine) Phase II Single-agent Soft-Tissue Sarcoma Study Presented at the 16th Annual EORTC-NCI-AACR Conference |
30-Sep-2004 |
| Keryx Biopharmaceuticals Files Shelf Registration Statement |
29-Sep-2004 |
| Keryx Biopharmaceuticals, Inc. to Present at the UBS Global Life Sciences Conference |
27-Sep-2004 |
| Keryx Biopharmaceuticals to Present at Punk Ziegel Diabetes Symposium |
21-Sep-2004 |
| Keryx Biopharmaceuticals, Inc. Initiates First Chemotherapy Combination Study for KRX-0401 (Perifosine) |
4-Aug-2004 |
| Keryx Biopharmaceuticals, Inc. to Present at The Banc of America Securities Specialty Pharmaceuticals Conference on Friday, July 30, 2004 |
27-Jul-2004 |
| Investigators from the Netherlands Cancer Institute Report Encouraging Results from Phase I Trial of KRX-0401 (Perifosine) in Combination with Radiotherapy at the 2004 American Society of Clinical Oncology (ASCO) Annual Meeting |
7-Jun-2004 |
| Keryx Biopharmaceuticals, Inc. to present at the Friedman Billings Ramsey 8th Annual Growth Investor Conference |
27-May-2004 |
| New Research Reveals Potential Utility of KRX-101 (Sulodexide) in the Prevention and Treatment of Cardiovascular Injury |
19-May-2004 |
| KERYX BIOPHARMACEUTICALS, INC. ADDED TO THE NASDAQ BIOTECHNOLOGY INDEX |
17-May-2004 |
| Keryx Biopharmaceuticals to Present at Banc of America Securities Health Care Conference |
13-May-2004 |
| Keryx Biopharmaceuticals to Present at Rodman & Renshaw Techvest Global Healthcare Conference |
6-May-2004 |
| Keryx Biopharmaceuticals to present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
21-Apr-2004 |
| Keryx Biopharmaceuticals, Inc. Announces Four New S.O.A.R. (Sulodexide Open Access Research) Collaborations for KRX-101 |
9-Mar-2004 |
| Keryx Biopharmaceuticals to Present at BIO CEO and Investor Conference |
19-Feb-2004 |
| Keryx Biopharmaceuticals, Inc. Announces $32 Million Private Equity Financing with Institutional Investors |
13-Feb-2004 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES THE CLOSING OF THE ACQUISITION |
6-Feb-2004 |
| Additional Data on Mechanism of Action of KRX-0401 (Perifosine) Published in January 15 Issue of Cancer Research |
5-Feb-2004 |
| Keryx Biopharmaceuticals to Present at Piper Jaffray Health Care Conference |
23-Jan-2004 |
| Keryx Biopharmaceuticals Adds Three Clinical-Stage Oncology Drug Candidates to its Pipeline, Including a Novel, First-in-Class, Oral AKT-Inhibitor in Phase II |
8-Jan-2004 |
| EKN SECURITIES INITIATES COVERAGE OF KERYX BIOPHARMACEUTICALS |
4-Dec-2003 |
| Keryx Biopharmaceuticals, Inc. Announces S.O.A.R. (Sulodexide Open Access Research) Program Collaboration with the University of Michigan |
25-Nov-2003 |
| KERYX BIOPHARMACEUTICALS, INC. RAISES $15 MILLION IN PRIVATE EQUITY TRANSACTION WITH INSTITUTIONAL INVESTORS |
18-Nov-2003 |
| Keryx Biopharmaceuticals, Inc. Initiates Phase II/III Clinical Program of KRX-101 (Sulodexide Gelcaps) for Treatment of Diabetic Nephropathy |
21-Oct-2003 |
| Keryx Biopharmaceuticals to Present at Rodman & Renshaw Techvest Healthcare Conference |
16-Oct-2003 |
| Keryx Biopharmaceuticals, Inc. Announces S.O.A.R. (Sulodexide Open Access Research) Program Collaboration with National Institutes of Health for KRX-101 |
3-Oct-2003 |
| Keryx Biopharmaceuticals, Inc. Announces First S.O.A.R. (Sulodexide Open Access Research) Program Collaboration for KRX-101 |
3-Oct-2003 |
| KERYX BIOPHARMACEUTICALS, INC. TO PRESENT AT THE BEAR STEARNS 16TH ANNUAL HEALTHCARE CONFERENCE |
5-Sep-2003 |
| KERYX BIOPHARMACEUTICALS LAUNCHES SOAR PROGRAM TO EXPAND STUDY OF KRX-101 (SULODEXIDE) |
12-Aug-2003 |
| The Collaborative Study Group to Conduct US-Based Phase II/III Clinical Program for KRX-101 (sulodexide) for the Treatment of Diabetic Nephropathy |
5-Aug-2003 |
| KERYX BIOPHARMACEUTICALS ANNOUNCES THE IMPLEMENTATION OF SIGNIFICANT COST REDUCTIONS |
2-Jan-2003 |
| KERYX ANNOUNCES SENIOR MANAGEMENT CHANGES |
23-Dec-2002 |
| KERYX PROVIDES UPDATE ON KRX-123, ITS DRUG CANDIDATE FOR HORMONE RESISTANT PROSTATE CANCER |
17-Dec-2002 |
| KERYX ANNOUNCES STOCK REPURCHASE PROGRAM |
18-Nov-2002 |
| KERYX REACHES AGREEMENT WITH FDA FOR KRX-101 SUBPART-H PLAN FOR DIABETIC KIDNEY DISEASE |
14-Nov-2002 |
| FRANCIS J.T. FILDES, PH.D. APPOINTED TO KERYX BOARD OF DIRECTORS |
15-Oct-2002 |
| KERYX EXTENDS INTERNATIONAL MANUFACTURING & NEGOTIATING RIGHTS FOR KRX-101, ITS PHASE 3 DRUG CANDIDATE FOR DIABETIC KIDNEY DISEASE |
3-Oct-2002 |
| KERYX FILES PROTOCOL WITH THE FDA FOR ITS PHASE 3 TRIAL OF KRX-101 FOR THE TREATMENT OF DIABETIC KIDNEY DISEASE |
17-Sep-2002 |
| KERYX CONTRACTS FOR HUMAN CLINICAL TRIAL STANDARD OF MANUFACTURING OF KRX-123 |
22-Aug-2002 |
| PUBLICATION IN THE JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY DESCRIBES THE EFFECTS OF KRX-101 IN DIABETIC KIDNEY DISEASE |
19-Jun-2002 |
| DR. LASTER TO PRESENT ON SIGNAL TRANSDUCTION IN DRUG DISCOVERY AT GLOBAL BIOTECH FORUM |
12-Jun-2002 |
| NEW PRE-CLINICAL FINDINGS SUPPORT KERYX'S IMMUNE MODULATOR DRUG CANDIDATE - KRX-211 |
30-May-2002 |
| KERYX BIOPHARMACEUTICALS, INC. (NASDAQ: KERX, AIM: KRX) FIRST QUARTER 2002 FINANCIAL RESULTS AND THE STATE OF THE COMPANY CONFERENCE CALL |
29-Apr-2002 |
| KERYX BIOPHARMACEUTICALS BEGINS PHASE II CLINICAL TRIAL OF KRX-101 FOR THE TREATMENT OF AIDS RELATED KIDNEY DISEASE |
14-Mar-2002 |
| KERYX BIOPHARMACEUTICALS TO INITIATE PHASE II CLINICAL TRIAL OF KRX-101 FOR THE TREATMENT OF AIDS RELATED KIDNEY DISEASE - HIV ASSOCIATED NEPHROPATHY (HIVAN) |
29-Jan-2002 |
| KERYX BIOPHARMACEUTICALS OBTAINS WORLDWIDE RIGHTS TO NOVEL SMALL MOLECULES TECHNOLOGY |
16-Jan-2002 |
| KERYX PRESIDENT, BENJAMIN CORN, M.D., ASSUMES ADDITIONAL ROLE OF CHIEF EXECUTIVE OFFICER |
26-Nov-2001 |
| KERYX APPOINTS PROF. RONY SEGER, PH.D. AS ITS CHIEF SCIENTIFIC OFFICER |
20-Sep-2001 |
| Keryx Biopharmaceuticals Granted Fast Track Status by the U.S. Food and Drug Administration |
6-Sep-2001 |
| KERYX AWARDED CRITICAL U.S. PATENT FOR GENE-BASED DRUG DISCOVERY INVOLVING KINASE TARGETED COMPOUNDS |
12-Feb-2001 |
| KERYX BIOPHARMACEUTICALS APPOINTS J. WILSON TOTTEN, M.D. AND MALCOM I. HOENLEIN TO BOARD OF DIRECTORS |
5-Feb-2001 |
| KERYX BIOPHARMACEUTICALS SECURES U.S. PATENT FOR USE OF KRX-101 AGAINST DIABETIC RETINOPATHY |
29-Jan-2001 |
| Keryx Biopharmaceuticals Provides Update on KRX-101 Clinical Development Program |
27-Sep-2000 |
|
| TITLE |
DATE |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2010 Financial Results |
10-May-2010 |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2009 Financial Results |
24-Mar-2010 |
| Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results |
9-Nov-2009 |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results |
5-Aug-2009 |
| Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results |
10-Nov-2008 |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results |
8-Aug-2008 |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results |
9-May-2008 |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results |
22-Feb-2008 |
| Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results |
24-Oct-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2007 Financial Results |
25-Jul-2007 |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2007 Financial Results |
25-Apr-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year End 2006 Financial Results |
8-Mar-2007 |
| Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2006 Financial Results |
1-Nov-2006 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2006 Financial Results |
31-Oct-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2006 Financial Results |
8-Aug-2006 |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2006 Financial Results |
4-May-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year End 2005 Financial Results |
1-Mar-2006 |
| Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2005 Financial Results |
3-Nov-2005 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2005 |
1-Aug-2005 |
| Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2005 Financial Results on Tuesday, August 2, at 8:30 A.M. EDT |
29-Jul-2005 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2005 FINANCIAL RESULTS |
4-May-2005 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND YEAR END 2004 FINANCIAL RESULTS |
7-Mar-2005 |
| KERYX BIOPHARMACEUTICALS, INC. TO HOLD CONFERENCE CALL ON FOURTH QUARTER AND YEAR-END 2004 FINANCIAL RESULTS ON TUESDAY, MARCH 8, AT 8:30 A.M. EST |
4-Mar-2005 |
| Keryx Biopharmaceuticals, Inc. to Hold Investor Conference Call on 2004 Third Quarter Financial Results Tomorrow, Tuesday, November 9th, at 8:30 a.m. EST |
8-Nov-2004 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2004 FINANCIAL RESULTS |
8-Nov-2004 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2004 FINANCIAL RESULTS |
3-Aug-2004 |
| Keryx Biopharmaceuticals, Inc. Announces First Quarter 2004 Financial Results |
7-May-2004 |
| Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter And Year End 2003 Financial Results |
26-Mar-2004 |
| KERYX BIOPHARMACEUTICALS, INC. TO HOLD CONFERENCE CALL ON 2003 FOURTH QUARTER AND FISCAL YEAR FINANCIAL RESULTS ON FRIDAY, MARCH 26, AT 10:00 A.M. EST |
24-Mar-2004 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2003 FINANCIAL RESULTS |
10-Nov-2003 |
| KERYX BIOPHARMACEUTICALS, INC. TO HOLD CONFERENCE CALL ON THIRD QUARTER 2003 FINANCIAL RESULTS ON TUESDAY, NOVEMBER 11, AT 10:00 A.M. EST |
7-Nov-2003 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2003 FINANCIAL RESULTS |
13-Aug-2003 |
| KERYX BIOPHARMACEUTICALS, INC. TO HOLD CONFERENCE CALL ON SECOND QUARTER 2003 FINANCIAL RESULTS ON THURSDAY, AUGUST 14, AT 10:00 A.M. EDT |
7-Aug-2003 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2003 FINANCIAL RESULTS |
14-May-2003 |
| KERYX BIOPHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND YEAR END 2002 FINANCIAL RESULTS AND REPORTS ON SUCCESSFUL IMPLEMENTATION OF RESTRUCTURING PROGRAM |
31-Mar-2003 |
| KERYX BIOPHARMACEUTICALS ANNOUNCES SECOND QUARTER 2002 RESULTS AND STRATEGIC REORGANIZATION DESIGNED TO SIGNIFICANTLY CUT COSTS AND MAINTAIN FOCUS ON LEADING PRODUCTS |
14-Aug-2002 |
| KERYX BIOPHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2002 FINANCIAL RESULTS |
1-May-2002 |
| KERYX BIOPHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND YEAR END 2001 FINANCIAL RESULTS |
25-Mar-2002 |
| Keryx Reports Third Quarter 2001 Financial Results |
13-Nov-2001 |
| Keryx Reports Second Quarter 2001 Financial Results |
13-Aug-2001 |
| KERYX REPORTS FIRST QUARTER 2001 FINANCIAL RESULTS |
15-May-2001 |
| Keryx Reports Fourth Quarter and Year End 2000 Financial Results |
29-Mar-2001 |
|
